{"id":"AIBD-0632","title":"FDA De Novo review of Clairity Allix5: AI predicts five-year breast cancer risk from screening mammograms at five US sites","summary":"In FDA's review of Clairity Allix5, the software predicted five-year breast cancer risk from 77,511 screening mammograms with an AUC of 0.70, above a goal of 0.64.","date_observed":"2025-05-30","date_basis":"source publication","date_precision":"day","benefit_status":"intended","source_collection":null,"source_entry":null,"account":"Clairity, Inc. of Austin, Texas, developed Allix5, deep learning software that reads a screening mammogram and predicts the chance that the patient will be diagnosed with breast cancer within five years. FDA reviewers describe a retrospective pivotal study of 77,511 exams from 44,112 patients at five screening sites in Atlanta, Fort Worth, Bedford, Sacramento and Folsom. None of these sites supplied data for training. Biopsy results and later mammograms served as the reference. The area under the time-dependent ROC curve was 0.70, above a performance goal of 0.64 based on the discrimination of traditional risk models. With current cancers excluded, the area was 0.66, and calibration met the pre-set tolerance in both groups. Black patients made up 37% of exams; the area was 0.67 for them and 0.73 for White patients. FDA granted the De Novo request on 30 May 2025. The study compared the software with a fixed goal drawn from traditional models, and the reviewers note that the software overestimated risk in the highest tenth of predictions for patients without current cancer.","category":"general benefit","unexpected":false,"purpose":"Allix5 was built to give a five-year breast cancer risk prediction from a screening mammogram to inform supplemental screening and risk reduction. The measured risk prediction is that purpose.","system":"Allix5","model_version":null,"developer":"Clairity, Inc.","deployer":"Clairity (retrospective study on mammograms from five US screening sites)","location":"Atlanta, Georgia; Fort Worth and Bedford, Texas; Sacramento and Folsom, California, United States","domain":"Healthcare","segment":null,"benefit_type":"Improved Task Accuracy","taxonomy_note":null,"registry_ids":{},"ratings":[{"group":"organizational","depth":null,"reason":"The discrimination was measured retrospectively against a fixed goal, and no screening site used the predictions to change care."}],"ai_role":{"status":"unassessed","statement":"The study compared the software with a fixed performance goal. It did not run traditional risk models on the same exams or compare care with and without the software."},"evidence":[{"kind":"regulatory document","citation":"U.S. Food and Drug Administration, Center for Devices and Radiological Health. De Novo classification request for Allix5 (DEN240047): decision summary. Granted 2025-05-30.","title":"De Novo classification request for Allix5 (DEN240047)","url":"https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN240047.pdf","date":"2025-05-30","written_by":"independent","quote":"This benefit is supported by the superior discrimination result (AUC(5): 0.70) with 95% confidence interval (0.69, 0.72) being above the performance goal of 0.64, informed by the traditional risk models."}],"replication":{"produced_by":["The software analyzed all four standard views of a bilateral screening mammogram.","Exams came from Hologic Lorad Selenia and Selenia Dimensions systems."],"must_hold":["The patient is eligible for screening mammography.","The clinician uses the risk output for supplemental screening or risk reduction decisions and does not use it to read the mammogram."],"echoes":[]},"paired_incident":null,"headline":"*Allix5* read five-year breast cancer risk from a mammogram","metric":"an AUC of 0.70, above a goal of 0.64","comparator":{"against":"A performance goal based on the discrimination of traditional risk models","before":"AUC goal of 0.64","after":"AUC 0.70 (95% CI 0.69 to 0.72)","basis":"assumed","quote":"The performance goal of 0.64 was selected based on the discrimination performance of traditional risk models","url":"https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN240047.pdf"},"later":null,"value":null,"developer_country":"United States","deployer_country":"United States","unrated_because":"The study was a retrodiction on stored mammograms in which the predictions informed no screening decision, so no realized outcome is reported for any group.","brief_notes":null,"brief":null,"revisions":[{"date":"2026-10-29","change":"Added the case.","source":"https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN240047.pdf","editor":"AIBD"},{"date":"2026-10-29","change":"Corrected the benefit status; revised the depth ratings.","source":null,"editor":"AIBD"}],"confidence":"found","shade":"high","claim_status":"Found by a regulator","claim_basis":"Sources: one independent regulatory document. The cited evidence includes no independent study or report.","case_jurisdictions":["United States"],"profile":{"case_id":"AIBD-0632","catalog_version":"1.0.0","source_fingerprint":"25447cdd008c05f3c528c1f3f4024df2ab272b64d0469865f2b3948041aa0fba","collection_refs":[{"collection_id":"aibd","version":"2026-10-29"},{"collection_id":"querist","version":"2026-10-25"}],"source_ids":["AIBD-0632-source-0001"],"families":{"strategic assessments":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"Editorial assignment.","review_state":"not_assessed","coverage":"partial","record_ids":[]},"evaluations":{"state":"value_present","value":{"kind":"identifiers","identifiers":["AIBD-0632-evaluation-1"],"role":"Evaluations of the benefit"},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":[],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"partial","record_ids":["AIBD-0632-evaluation-1"]},"monetary observations":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"Editorial assignment.","review_state":"not_assessed","coverage":"partial","record_ids":[]},"institutional decisions":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"Editorial assignment.","review_state":"not_assessed","coverage":"partial","record_ids":[]}},"fields":{"actors[]":{"state":"value_present","value":{"kind":"record_fields","fields":{"developer":"Clairity, Inc.","deployer":"Clairity (retrospective study on mammograms from five US screening sites)"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["developer","deployer"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"actors[].ownership_control":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"ai_contribution":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"ai_relationship":{"state":"value_present","value":{"kind":"record_fields","fields":{"category":"general benefit","ai_role":{"status":"unassessed","statement":"The study compared the software with a fixed performance goal. It did not run traditional risk models on the same exams or compare care with and without the software."}}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["ai_role","category"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"assessments[].alternatives":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"assessments[].assessor_date":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"assessments[].depth":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"The record revision removed the mapped value.","record_fields":["ratings"],"source_refs":[]},"reason":"The revised record no longer states this information.","review_state":"not_assessed","coverage":"partial"},"assessments[].display_confidence":{"state":"value_present","value":{"kind":"structured","data":{"confidence":"high","evidence_word":"found","claim_status":"Found by a regulator","basis":"Sources: one independent regulatory document. The cited evidence includes no independent study or report.","interpretation":"Existing display rule preserved; the richer outcome-specific confidence question still needs review."}},"provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"assessments[].rationale":{"state":"value_present","value":{"kind":"record_fields","fields":{"ratings":[{"group":"organizational","reason":"The discrimination was measured retrospectively against a fixed goal, and no screening site used the predictions to change care."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["ratings"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"assessments[].rubric_version":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"assessments[].status_basis":{"state":"value_present","value":{"kind":"text","text":"Intended. The study applied the software retrospectively to stored mammograms and the predictions informed no screening decision, so the sources report no realized benefit."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["benefit_status"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Intended. The study applied the software retrospectively to stored mammograms and the predictions informed no screening decision, so the sources report no realized benefit.","inferred":false}},"assessments[].target":{"state":"value_present","value":{"kind":"record_fields","fields":{"ratings":[{"group":"organizational","reason":"The discrimination was measured retrospectively against a fixed goal, and no screening site used the predictions to change care."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["ratings"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"availability":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"brief":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"case_kind":{"state":"value_present","value":{"kind":"structured","data":{"classification":"evaluation or study","answer":"The case describes an evaluation or a study. A regulatory review of a retrospective prognostic validation study.","scope":"The period and activity described in the case."}},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["account","evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"The case describes an evaluation or a study. A regulatory review of a retrospective prognostic validation study.","inferred":false}},"case_links[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Compared with the incidents in the AI Incident Database snapshot of 26 October 2026.","record_fields":["paired_incident"],"source_refs":[]},"reason":"No incident in the AI Incident Database snapshot of 26 October 2026 concerns the same kind of system harming the same kind of stakeholder.","review_state":"reviewed","coverage":"partial"},"claims[].evidence_links":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"claims[].evidence_strength":{"state":"value_present","value":{"kind":"structured","data":{"answer":"Found by a regulator. Sources: one independent regulatory document. The cited evidence includes no independent study or report.","evidence_word":"found","claim_status":"Found by a regulator"}},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Found by a regulator. Sources: one independent regulatory document. The cited evidence includes no independent study or report.","inferred":false}},"claims[].missingness":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"claims[].proposition":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"cross_border_flows[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"decisions[].action_outcome":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"institutional decisions"},"decisions[].grounds":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"institutional decisions"},"decisions[].institution_task":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"institutional decisions"},"decisions[].success_criterion":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"institutional decisions"},"deployment_stage":{"state":"value_present","value":{"kind":"structured","data":{"classification":"laboratory test","answer":"The system was tested in a laboratory. A retrospective study on archived mammograms; the software did not guide care.","scope":"The period and activity described in the case."}},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["account","evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"The system was tested in a laboratory. A retrospective study on archived mammograms; the software did not guide care.","inferred":false}},"economics[].amount":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].costs[]":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].counterfactual":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].currency_price_basis":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].gross_net":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].measure_type":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].period_unit":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].realization":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].recipient_payer":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].return_payback":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"economics[].valuation_method":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"monetary observations"},"evaluations[].ai_uplift":{"state":"value_present","value":{"kind":"text","text":"Not isolated."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Not isolated.","inferred":false}},"evaluations[].comparator":{"state":"value_present","value":{"kind":"text","text":"Fixed performance goal of 0.64."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Fixed performance goal of 0.64.","inferred":false}},"evaluations[].design":{"state":"value_present","value":{"kind":"text","text":"Other."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Other.","inferred":false}},"evaluations[].effect":{"state":"value_present","value":{"kind":"text","text":"AUC 0.70 overall; 0.66 excluding current cancers; calibration endpoints met."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"AUC 0.70 overall; 0.66 excluding current cancers; calibration endpoints met.","inferred":false}},"evaluations[].exposure":{"state":"value_present","value":{"kind":"text","text":"One screening mammogram per exam."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"One screening mammogram per exam.","inferred":false}},"evaluations[].id":{"state":"value_present","value":{"kind":"identifiers","identifiers":["AIBD-0632-evaluation-1"],"role":"Evaluations of the benefit"},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Other.","inferred":false}},"evaluations[].measurement_method":{"state":"value_present","value":{"kind":"text","text":"Retrospective validation of five-year risk predictions against biopsy-proven cancer and follow-up mammography, adjusted for censoring."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Retrospective validation of five-year risk predictions against biopsy-proven cancer and follow-up mammography, adjusted for censoring.","inferred":false}},"evaluations[].metric":{"state":"value_present","value":{"kind":"text","text":"Time-dependent AUC at five years and calibration (modified GND test)."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Time-dependent AUC at five years and calibration (modified GND test).","inferred":false}},"evaluations[].reproduction_materials":{"state":"value_present","value":{"kind":"text","text":"None reported."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"None reported.","inferred":false}},"evaluations[].setting_sample":{"state":"value_present","value":{"kind":"text","text":"77,511 exams from 44,112 patients at five US screening sites not used for training."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"77,511 exams from 44,112 patients at five US screening sites not used for training.","inferred":false}},"evaluations[].uncertainty_limitations":{"state":"value_present","value":{"kind":"text","text":"Retrospective; no same-sample comparison with traditional models; overestimation in the highest decile for patients without current cancer."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Retrospective; no same-sample comparison with traditional models; overestimation in the highest decile for patients without current cancer.","inferred":false}},"external_references[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"follow_up[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"human_oversight":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"id":{"state":"value_present","value":{"kind":"record_fields","fields":{"id":"AIBD-0632"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["id"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"infrastructure_dependencies[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].beneficiaries":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].beneficiary_count":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].benefit_type":{"state":"value_present","value":{"kind":"record_fields","fields":{"benefit_type":"Improved Task Accuracy"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["benefit_type"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"outcomes[].claim":{"state":"value_present","value":{"kind":"record_fields","fields":{"account":"Clairity, Inc. of Austin, Texas, developed Allix5, deep learning software that reads a screening mammogram and predicts the chance that the patient will be diagnosed with breast cancer within five years. FDA reviewers describe a retrospective pivotal study of 77,511 exams from 44,112 patients at five screening sites in Atlanta, Fort Worth, Bedford, Sacramento and Folsom. None of these sites supplied data for training. Biopsy results and later mammograms served as the reference. The area under the time-dependent ROC curve was 0.70, above a performance goal of 0.64 based on the discrimination of traditional risk models. With current cancers excluded, the area was 0.66, and calibration met the pre-set tolerance in both groups. Black patients made up 37% of exams; the area was 0.67 for them and 0.73 for White patients. FDA granted the De Novo request on 30 May 2025. The study compared the software with a fixed goal drawn from traditional models, and the reviewers note that the software overestimated risk in the highest tenth of predictions for patients without current cancer.","benefit_type":"Improved Task Accuracy"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["account","benefit_type"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"outcomes[].distribution":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].duration":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].id":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].stakeholder_group":{"state":"value_present","value":{"kind":"record_fields","fields":{"ratings":[{"group":"organizational","reason":"The discrimination was measured retrospectively against a fixed goal, and no screening site used the predictions to change care."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["ratings"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"outcomes[].status":{"state":"value_present","value":{"kind":"text","text":"Intended. The study applied the software retrospectively to stored mammograms and the predictions informed no screening decision, so the sources report no realized benefit."},"provenance":{"kind":"source_review","basis":"Editorial assignment.","record_fields":["benefit_status"],"source_refs":["AIBD-0632-source-0001"],"reviewed_on":"2026-10-29"},"review_state":"reviewed","coverage":"complete","display":{"answer":"Intended. The study applied the software retrospectively to stored mammograms and the predictions informed no screening decision, so the sources report no realized benefit.","inferred":false}},"outcomes[].tradeoffs":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"outcomes[].unexpected":{"state":"value_present","value":{"kind":"record_fields","fields":{"unexpected":false,"purpose":"Allix5 was built to give a five-year breast cancer risk prediction from a screening mammogram to inform supplemental screening and risk reduction. The measured risk prediction is that purpose."}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["unexpected","purpose"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"places[]":{"state":"value_present","value":{"kind":"record_fields","fields":{"location":"Atlanta, Georgia; Fort Worth and Bedford, Texas; Sacramento and Folsom, California, United States","developer_country":"United States","deployer_country":"United States"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["location","developer_country","deployer_country"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"purpose":{"state":"value_present","value":{"kind":"record_fields","fields":{"purpose":"Allix5 was built to give a five-year breast cancer risk prediction from a screening mammogram to inform supplemental screening and risk reduction. The measured risk prediction is that purpose."}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["purpose"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"record_dates":{"state":"value_present","value":{"kind":"record_fields","fields":{"date_observed":"2025-05-30","date_basis":"source publication","date_precision":"day","revisions":[{"date":"2026-10-29","change":"Added the case.","source":"https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN240047.pdf","editor":"AIBD"},{"date":"2026-10-29","change":"Corrected the benefit status; revised the depth ratings.","editor":"AIBD"}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["date_observed","date_basis","date_precision","revisions"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"replication.attempts[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"replication.conditions":{"state":"value_present","value":{"kind":"record_fields","fields":{"replication":{"produced_by":["The software analyzed all four standard views of a bilateral screening mammogram.","Exams came from Hologic Lorad Selenia and Selenia Dimensions systems."],"must_hold":["The patient is eligible for screening mammography.","The clinician uses the risk output for supplemental screening or risk reduction decisions and does not use it to read the mammogram."],"echoes":[]}}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["replication"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"revision_history[]":{"state":"value_present","value":{"kind":"record_fields","fields":{"revisions":[{"date":"2026-10-29","change":"Added the case.","source":"https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN240047.pdf","editor":"AIBD"},{"date":"2026-10-29","change":"Corrected the benefit status; revised the depth ratings.","editor":"AIBD"}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["revisions"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"sector":{"state":"value_present","value":{"kind":"record_fields","fields":{"domain":"Healthcare"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["domain"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"sources[].access_version":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"sources[].citation_locator":{"state":"value_present","value":{"kind":"record_fields","fields":{"evidence":[{"kind":"regulatory document","citation":"U.S. Food and Drug Administration, Center for Devices and Radiological Health. De Novo classification request for Allix5 (DEN240047): decision summary. Granted 2025-05-30.","title":"De Novo classification request for Allix5 (DEN240047)","url":"https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN240047.pdf","date":"2025-05-30","written_by":"independent","quote":"This benefit is supported by the superior discrimination result (AUC(5): 0.70) with 95% confidence interval (0.69, 0.72) being above the performance goal of 0.64, informed by the traditional risk models."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"sources[].id":{"state":"value_present","value":{"kind":"identifiers","identifiers":["AIBD-0632-source-0001"],"role":"Existing evidence items, in their original order"},"provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"review_state":"record_mapped","coverage":"complete"},"sources[].language":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"sources[].relationship":{"state":"value_present","value":{"kind":"record_fields","fields":{"evidence":[{"kind":"regulatory document","citation":"U.S. Food and Drug Administration, Center for Devices and Radiological Health. De Novo classification request for Allix5 (DEN240047): decision summary. Granted 2025-05-30.","title":"De Novo classification request for Allix5 (DEN240047)","url":"https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN240047.pdf","date":"2025-05-30","written_by":"independent","quote":"This benefit is supported by the superior discrimination result (AUC(5): 0.70) with 95% confidence interval (0.69, 0.72) being above the performance goal of 0.64, informed by the traditional risk models."}]}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["evidence"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"sources[].upstream_sources":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"strategic_assessments[]":{"state":"unresolved","review_state":"not_assessed","coverage":"partial","family":"strategic assessments"},"summary":{"state":"value_present","value":{"kind":"record_fields","fields":{"summary":"In FDA's review of Clairity Allix5, the software predicted five-year breast cancer risk from 77,511 screening mammograms with an AUC of 0.70, above a goal of 0.64.","account":"Clairity, Inc. of Austin, Texas, developed Allix5, deep learning software that reads a screening mammogram and predicts the chance that the patient will be diagnosed with breast cancer within five years. FDA reviewers describe a retrospective pivotal study of 77,511 exams from 44,112 patients at five screening sites in Atlanta, Fort Worth, Bedford, Sacramento and Folsom. None of these sites supplied data for training. Biopsy results and later mammograms served as the reference. The area under the time-dependent ROC curve was 0.70, above a performance goal of 0.64 based on the discrimination of traditional risk models. With current cancers excluded, the area was 0.66, and calibration met the pre-set tolerance in both groups. Black patients made up 37% of exams; the area was 0.67 for them and 0.73 for White patients. FDA granted the De Novo request on 30 May 2025. The study compared the software with a fixed goal drawn from traditional models, and the reviewers note that the software overestimated risk in the highest tenth of predictions for patients without current cancer."}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["summary","account"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"systems[].autonomy_permissions":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].component_role":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].deployment_configuration":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].inputs_outputs":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].model_name":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].model_version":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"systems[].product_name":{"state":"value_present","value":{"kind":"record_fields","fields":{"system":"Allix5"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["system"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"systems[].provider":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"taxonomy_crosswalks[]":{"state":"unresolved","provenance":{"kind":"curatorial","basis":"Editorial assignment.","record_fields":[],"source_refs":[]},"reason":"This is an explicit unresolved assignment: the sources on record do not settle this question.","review_state":"not_assessed","coverage":"partial"},"title":{"state":"value_present","value":{"kind":"record_fields","fields":{"title":"FDA De Novo review of Clairity Allix5: AI predicts five-year breast cancer risk from screening mammograms at five US sites","headline":"*Allix5* read five-year breast cancer risk from a mammogram"}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["title","headline"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"},"version":{"state":"value_present","value":{"kind":"identifiers","identifiers":["79f30d3a2086cb997f1cb34bba43b736577ca32adf935bbf9be9e70a6ed9a576"],"role":"SHA-256 of the complete public case and its assessments"},"provenance":{"kind":"curatorial","basis":"SHA-256 of the public case, its assessments, and its displayed answers and notes, excluding its own identifier and the derived coverage summary.","record_fields":[],"source_refs":[]},"review_state":"record_mapped","coverage":"complete"},"workflow":{"state":"value_present","value":{"kind":"record_fields","fields":{"account":"Clairity, Inc. of Austin, Texas, developed Allix5, deep learning software that reads a screening mammogram and predicts the chance that the patient will be diagnosed with breast cancer within five years. FDA reviewers describe a retrospective pivotal study of 77,511 exams from 44,112 patients at five screening sites in Atlanta, Fort Worth, Bedford, Sacramento and Folsom. None of these sites supplied data for training. Biopsy results and later mammograms served as the reference. The area under the time-dependent ROC curve was 0.70, above a performance goal of 0.64 based on the discrimination of traditional risk models. With current cancers excluded, the area was 0.66, and calibration met the pre-set tolerance in both groups. Black patients made up 37% of exams; the area was 0.67 for them and 0.73 for White patients. FDA granted the De Novo request on 30 May 2025. The study compared the software with a fixed goal drawn from traditional models, and the reviewers note that the software overestimated risk in the highest tenth of predictions for patients without current cancer.","replication":{"produced_by":["The software analyzed all four standard views of a bilateral screening mammogram.","Exams came from Hologic Lorad Selenia and Selenia Dimensions systems."],"must_hold":["The patient is eligible for screening mammography.","The clinician uses the risk output for supplemental screening or risk reduction decisions and does not use it to read the mammogram."],"echoes":[]}}},"provenance":{"kind":"legacy_record","basis":"Editorial assignment.","record_fields":["account","replication"],"source_refs":[]},"review_state":"record_mapped","coverage":"partial"}},"summary":{"total":91,"addressed":91,"known":40,"reviewed":17,"reviewed_complete":16,"reviewed_partial":1,"record_mapped":24,"review_not_assessed":50,"not_assessed":0,"complete":false,"by_state":{"value_present":40,"not_reported":0,"unresolved":51,"not_assessed":0,"not_applicable":0,"withheld":0,"source_unavailable":0}}},"presentation_version":"df46a285f98941f3aa6638918745b7300a37c4821d79e6b8525464a40eaa1304"}